Beautiful Virgin Islands

Tuesday, Mar 21, 2023

Retired head of vaccine R&D at Pfizer about COVID vaccines: “We flew the aeroplane while we were still building it”

Retired head of vaccine R&D at Pfizer about COVID vaccines: “We flew the aeroplane while we were still building it”

Recently retired head of vaccine R&D at Pfizer, Kathrin Jansen, discusses the lightning speed development of SARS-CoV-2 vaccines — and the implications for vaccine platforms. Recently retired head of vaccine R&D at Pfizer, Kathrin Jansen, discusses the lightning speed development of SARS-CoV-2 vaccines — and the implications for vaccine platforms.

The unique power of vaccines to prevent disease captured Kathrin Jansen’s imagination at an early age. “I remember lining up in the school auditorium for my smallpox vaccine. I thought it was amazing: one shot and you’re done. Great!”

Vaccines have not provided quite such a simple solution for COVID, but the ultra-rapid development of these products has been a game-changing lifeline for a world in the throes of a viral pandemic. Jansen, who has now stepped down as Pfizer’s head of vaccine R&D, leaves the SARS-CoV-2 vaccine Comirnaty as an impressive capstone to a massive career showcasing the public health possibilities of vaccination.

Originally trained as a microbiologist in Germany and the USA, Jansen jumped to industry early on in her career. Over the course of 30 years, she has wielded different platforms to deliver some of industry’s most impactful vaccines. While at Merck & Co., for example, she drove the development of the recombinant virus-mimicking coat protein that enabled the human papillomavirus vaccine Gardasil, preventing the viral infection that causes cervical cancer. Later, at Pfizer, she embraced the protein–polysaccharide conjugate technology that led to the multivalent Prevnar vaccines for pneumococcal disease.

When the pandemic struck in 2020, Pfizer was already collaborating with BioNTech on mRNA vaccines for influenza. The partners ran with this experimental platform — and compressed vaccine development timelines from ten years to just nine months. In December 2020, Comirnaty became the first SARS-CoV-2 vaccine to secure authorization in the UK, the USA and other countries.

Over 1 billion doses of the vaccine have now been administered in the USA and Europe. Total sales for this record-breaking vaccine are forecast to exceed US$70 billion by the end of 2022.

But this success has brought the issue of vaccine pushback into sharp focus. “I find it astounding, after all that humankind went through, how many people still do not see the value of vaccines and don’t get immunized,” says Jansen. “Society now just accepts 400 COVID deaths every day in the USA, for example. This is just mind-boggling.”


How did you develop a vaccine for SARS-CoV-2 so quickly?

Over the years we had built a strong infrastructure, particularly through the pneumococcal conjugate vaccine programmes. But COVID changed everything in terms of how to approach the end-to-end vaccine R&D concept, driven by the enormous urgency.

[In March 2020] when our CEO said, “Get it done before the end of the year,” I said, “This is crazy!” But money was not an issue — and, then, you can do amazing things in an amazing amount of time.

We got creative — we couldn’t wait for data, we had to do so much ‘at risk’. We flew the aeroplane while we were still building it.

All the bureaucracy fell away. We were doing things in parallel, looking at data and doing the manufacturing. Usually, manufacturing doesn’t get involved until years into a programme. I remember those calls with my manufacturing colleagues; I said, “We have four different constructs, get all four ready.” Then later we narrowed it down. We threw a lot away that wasn’t working, but we always had other things already at scale to take forward.

Why did you choose an mRNA platform for the vaccine?

I have experienced many different approaches to vaccine development, so I knew what would likely not work [against SARS-CoV-2] and what may work.

I was not willing to forego getting a strong T cell response, which steered us away from protein platforms.

Then having had the opportunity to work with BioNTech, it was clear to me that mRNA had to be the platform with the highest chance of success. I didn’t know whether it was possible at that time. All I knew was that, if anything works, it should be mRNA because it ticks all of the arms of the immune system — you get good T cell responses, antibodies and innate responses. T cell and innate responses, particularly for an older population, are where things usually fall down [with other platforms].

Another reason the mRNA platform came out as the front-runner was that we think you can boost as much and as long as you want and not get immune responses to the vector itself — the mRNA. If you use a viral vector, your immune response to the vector can tune down your response to the target — in this case, the SARS-CoV-2 spike protein.

But the mRNA platform wasn’t ready for prime time. There were stability issues, formulation issues, that we needed to solve. In 2020, it was only a research process and it needed to be scaled up. Usually, you start with a small reactor, and then you go to bigger and bigger reactors. We didn't have time to do this. Instead, we just cloned this relatively small-scale research process many times and over multiple sites to get to the capacity to produce billions of doses.


How did it feel to get an approval less than one year into the programme?

It was amazing. It showed what can be achieved if you put your mind to it, and if you put the resources to it, and if you also — which was unique — have the scientific community come together. Having information in those preprint servers or made rapidly available by publishers such as Nature, we could see in real time every new discovery. It wasn’t about who publishes first, but a willingness to share scientific data for the sake of dealing with this beast of the pandemic.


How replicable is that development speed?

This was a model for special circumstances, where people were willing to do whatever it takes. But we were working around the clock and there was a lot of burnout. It’s not a model for the future, where you can aim to do everything that way. It’s not sustainable.


Do you think mRNA vaccine platforms will now become more dominant?

For some viral diseases, the mRNA platform is super, and there’s a bunch of mRNA candidates now that are being worked on. [Target pathogens include influenza, rabies and others].

But the jury is still out on whether mRNA vaccines could play a role against some of the bacterial pathogens. For example, for the pneumococcal conjugate vaccines, you need a protein carrier and a polysaccharide that has been derived from the pathogen. That doesn’t lend itself to mRNA at all.


How has your experience across such varied pathogens shaped your general approach to vaccine R&D?

You can’t just take a technology and throw it at every pathogen — it’s not going to work. I was always interested in finding the right technology. Some companies are focused on a single technology for vaccines. But one hat doesn’t fit all heads. When you look at the portfolio at Pfizer, for example, we have mRNA, protein and polysaccharide conjugate vaccines. When we need a new technology, we get the new technology. That’s why we got into mRNA, for example — because I said, “All the other technologies have been tried and we are not getting a game-changing flu vaccine by sticking to the things that we know.”

Venturing into something new can be nerve-wracking, but I’ve always been willing to change according to where the science told me to go.


Apart from platform choice, what else is important for successful vaccine R&D?

Understanding of the pathogen is crucial.

A good example is RSV [respiratory syncytial virus]. People have worked on RSV vaccines for over 60 years and there have been some spectacular failures because people were targeting the wrong conformation of the viral fusion protein. It’s a protein on the virus surface that docks to the host cell and undergoes a conformation change that allows the virus to get into those cells. If you target the postfusion conformation, you don’t get a protective immune response. But people didn’t realise this until 2013, when researchers were able to stabilize and determine the crystal structure of the prefusion conformation.

We had ‘parked’ our RSV R&D programme, but when this data came out, we jumped on it and did some additional structural work. Now we have had spectacular results in a phase III study in adults. [Recent topline results show 85.7% vaccine efficacy against severe RSV-associated disease in adults over 60. Pfizer plans to file for approval by year end, competing with GSK for a first RSV vaccine to market.]

To succeed [in vaccine development] we also need to understand the pathogen–host interplay, and what are the true correlates of immune protection. For example, Pfizer is still working on Staphylococcus aureus. We tried to develop a protein–polysaccharide conjugate vaccine, and that failed miserably [in 2019]. Our problem is we just do not understand fully what a protective immune response against this pathogen needs to look like. Something is missing to understand how you keep that bacterium in check and protect yourself.

As a field, we’re still plagued by not having enough knowledge. I wish there would be more emphasis on understanding the biology, because a single entity like a company or a lab cannot do it alone. This has to be a coordinated effort on a pathogen-by-pathogen basis. It takes a lot of money. This is academic research involving huge studies that take years.


Along similar lines, how prepared are we for another pandemic?

When SARS-CoV-2 hit, I realized how absolutely ill-prepared we were as a community, not just in the USA, but everywhere.

When there’s a ‘crisis’ it can work, but it was such a fire drill. Why not be more prepared?

It’s all about investment, political will and cutting the bureaucracy. The lack of high-level learnings really concerns me.


Given the overall role of data sharing and basic research in vaccine development in general, and Comirnaty revenues in the case of COVID, how balanced do you think the reward system is?

It’s a complex question. You have to bear in mind that Pfizer and BioNTech covered the enormous R&D costs of Comirnaty, and didn’t get lots of government funding like other companies. And there were huge opportunity costs for other programmes because we drafted the vast majority of our researchers and support staff to work on this vaccine. Also, the strategy for vaccination against SARS-CoV-2 variants was based on the science and data coming from Pfizer and others.

So I do believe that there is balance overall, given the enormous impact of Comirnaty for public health globally and considering that there undoubtedly will be a next pandemic — best addressed by companies with the appropriate know-how and infrastructure.


Vaccines also have the potential to help address the growing, global infectious disease problem of antimicrobial resistance. What do you see as the main opportunities there?

There’s a fantastic opportunity to address antimicrobial resistance just by preventing disease in the first place. Pneumococcal conjugate vaccines are a classic example. Some of the data show that after the introduction of [multivalent conjugate vaccines], antimicrobial resistance was much reduced. Because you prevent the disease, you’re not giving antibiotics, and that slows the development of antimicrobial resistance.

But even vaccines for viral diseases present an opportunity to combat antibiotic resistance. Oftentimes when people have a respiratory tract infection, they get prescribed antibiotics because they haven’t been tested for the actual pathogen. There’s a lot of inappropriate use of antibiotics, and you can address this indirectly by preventing infections with respiratory pathogens. RSV will be a great example, because it’s so common.


What are you planning to do next?

I’m still working that out but, meanwhile, I’m teaching a vaccine course at The Wistar Institute. COVID has shown the power of vaccines. It’s important that we give the next generation of vaccinologists the enthusiasm about what an important field it is, to convey to them how far we have come already and how much more there is to do.

Comments

Oh ya 127 days ago
Well lets just hope she is at the head of the line at the Nuremberg 2.0 trials.. Google sudden death. Talk to undertakers and casket makers and they will tell you how their business are booming with the rise in excess deaths. Talk to your friends that work at hospitals like i did and hear about heart problems in young males along with increases in diabetes and cancer and women having their babies die in the womb. Research the poor countries that did not have the money to buy this clot shot and look at the stats. They had few deaths and are not losing folks like heavy vaxxed countries like Israel, USA etc. If you took this shot 1st get right with your God and 2nd start reading on what you can do to try to stay alive as these spike proteins are starting to block your circulatory system a good start would be FLCCC

Newsletter

Related Articles

Beautiful Virgin Islands
Close
0:00
0:00
Credit Suisse's Scandalous History Resulted in an Obvious Collapse - It's time for regulators who fail to do their job to be held accountable and serve as an example by being behind bars.
I have a dream, MLK inspiring speech
Home Secretary Suella Braverman tours potential migrant housing in Rwanda as asylum deal remains mired in legal challenges
Aretha Franklin, Marvis Staples - Oh Happy Day
Paris Rioting vs Macron anti democratic law
BVI Freedom Song
'Sexual Fantasy' Assignment At US School Outrages Parents
Billy Preston - You Can't Beat God Giving (Live)
Credit Suisse to borrow $54 billion from Swiss central bank
VIRGIN ISLANDS REGGAE CARIBBEAN RIDDIMZ
Russian Hackers Preparing New Cyber Assault Against Ukraine
Oh Happy Day Edwin Hawkins - Anthony Brown w FBCG Combined Choir
Jeremy Hunt insists his Budget will get young parents and over-50s back into work
'Stand by Me' performed by Karen Gibson and The Kingdom Choir
If this was in Tehran, Moscow or Hong Kong
National Anthem of the British Virgin Islands - Oh, Beautiful Virgin
Nashville police officer, and a female driver shooting one another
Hello Dolly
TRUMP: "Standing before you today, I am the only candidate who can make this promise: I will prevent World War III."
for KING & COUNTRY - Amen (Reborn) [feat. Lecrae & The WRLDFMS Tony Wi
Mexican President Claims Mexico is Safer than the U.S.
Bob Marley - Get Up Stand Up
A brief banking situation report
Yes He Can
Lady bites police officer and gets instantly reaction
What A Friend We Have In Jesus
We are witnessing widespread bank fails and the president just gave a 5 min speech then walked off camera.
Unforgettable
Donald Trump's asked by Tucker Carlson question on if the U.S. should support regime change in Russia?.
Touch The Hem Of His Garment
Good news: The U.S. government is now guaranteeing all deposits, held by, Silicon Valley Bank, and the funds are available as of today
The Lord's Prayer
Silicon Valley Bank exec was Lehman Brothers CFO
THE GOD MOVEMENT...BEAUTIFUL BVI
In a potential last-ditch effort, HSBC is considering a rescue deal to save Silicon Valley Bank UK from insolvency
Siyahamba
BBC Director General, Tim Davie, has apologized, but not resigned, yet, following the disruption of sports programmes over the weekend
Ray Charles And The Voices Of Jubilaton, Oh, Happy Day
A Mississippian man, who was once considered a “ticking time bomb,” has lost a whopping 165 kilograms! What motivated this incredible transformation?
Ramblin' Rose
Elon Musk Is Planning To Build A Town In Texas For His Employees
Protoje - Who Knows ft. Chronixx
The Silicon Valley Bank’s collapse effect is spreading around the world, affecting startup companies across the globe
Pressure - Virgin Islands Nice
City officials in Berlin announced on Thursday that all swimmers at public pools will soon be allowed to swim topless
Phil Wickham - House Of The Lord
Fitness scam
My God Is Real (Yes, God Is Real)
Market Chaos as USDC Loses Peg to USD after $3.3 Billion Reserves Held by Silicon Valley Bank Closed.
The Lion King Circle of Life by LEBO M. — LIVE at the HAVASI Symphonic
A primitive judge in Australia sparked outrage when he told a breastfeeding woman to leave his courtroom for being “a distraction"
Louis Armstrong - When The Saints Go Marching In
Barcelona is feeling the heat as they face corruption charges over payments to former vice-president of Spain's referees' committee, Jose Maria Enriquez Negreira
Kanye West Sunday Service - hallelujah, salvation, and glory
Senator Tom Cotton: If the Mexican Government Won’t Stop Cartels from Killing Americans, Then U.S. Government Should
Jonathan Nelson - I Believe (Island Medley
Banking regulators close SVB, the largest bank failure since the financial crisis
From The Virgin Islands Sqad Up
The unelected UK Prime Minister Rishi Sunak, an immigrant himself, defends new controversial crackdown on illegal migration
Common, John Legend - Glory
Old clip of Bill Gates saying Ukraine is a big, fat, corrupt sinkhole is going viral
Anthony Evans vs. Jesse Campbell - If I Ain't Got You
Man’s penis amputated by mistake after he’s wrongly diagnosed with a tumour
I have a dream, MLK inspiring speech
In a major snub to Downing Street's Silicon Valley dreams, UK chip giant Arm has dealt a serious blow to the government's economic strategy by opting for a US listing
Aretha Franklin, Marvis Staples - Oh Happy Day
JP Morgan Becomes First Bank to Predict UK Will Avoid Recession
BVI Freedom Song
JP Morgan Becomes First Bank to Predict UK Will Avoid Recession
Billy Preston - You Can't Beat God Giving (Live)
How do stolen goods end up on Amazon, eBay and Facebook Marketplace?
VIRGIN ISLANDS REGGAE CARIBBEAN RIDDIMZ
It's the question on everyone's lips: could a four-day workweek be the future of employment?
Oh Happy Day Edwin Hawkins - Anthony Brown w FBCG Combined Choir
Is Gold the Ultimate Safe Haven Asset in Times of Uncertainty?
'Stand by Me' performed by Karen Gibson and The Kingdom Choir
Spain officials quit over trains that were too wide for tunnels...
National Anthem of the British Virgin Islands - Oh, Beautiful Virgin
Don Lemon, a CNN anchor, has provided a list of five areas that he believes the black community needs to address.
Hello Dolly
Hello. Here is our news digest from London.
for KING & COUNTRY - Amen (Reborn) [feat. Lecrae & The WRLDFMS Tony Wi
Corruption and Influence Buying Uncovered in International Mainstream Media: Investigation Reveals Growing Disinformation Mercenaries
Bob Marley - Get Up Stand Up
Givenchy Store in New York Robbed of $50,000 in Merchandise
Yes He Can
European MP Clare Daly condemns US attack on Nord Stream
What A Friend We Have In Jesus
Former U.S. President Carter will spend his remaining time at home and receive hospice care instead of medication
Unforgettable
Tucker Carlson called Trump a 'demonic force'
Touch The Hem Of His Garment
×